Hypertrophic cardiomyopathy screening

Hypertrophic Cardiomyopathy (HCM) Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Cardiomyopathy, Sports medicine, Medical specialties, Hypertrophic cardiomyopathy, HCM, Clinical medicine, Hypertrophic cardiomyopathy screening

The "Hypertrophic Cardiomyopathy (HCM) - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertrophic Cardiomyopathy (HCM) - Epidemiology forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Hypertrophic Cardiomyopathy (HCM)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Hypertrophic Cardiomyopathy (HCM) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Hypertrophic Cardiomyopathy (HCM) epidemiology segmented as the Prevalent Cases of Hypertrophic Cardiomyopathy (HCM), Diagnosed Cases of Hypertrophic Cardiomyopathy (HCM), Type-specific Cases of HCM, Gender-specific Cases of HCM.

U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Retrieved on: 
Friday, March 19, 2021
Health, FDA, General Health, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Cardiomyopathy, Medical specialties, Hypertrophic cardiomyopathy, Sports medicine, Bristol Myers Squibb, Clinical medicine, Companies, Hypertrophic cardiomyopathy screening, Mavacamten, EXPLORER-HCM, Hypertrophic Cardiomyopathy, Bristol Myers Squibb

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin, for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin, for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
  • We are committed to supporting patients in need of HCM treatment and look forward to working with the FDA.
  • The NDA submission was based on the results of the pivotal Phase 3 EXPLORER-HCM trial, which evaluated mavacamten in patients with symptomatic oHCM versus placebo.
  • The EXPLORER-HCM Phase 3 trial enrolled a total of 251 patients with symptomatic (NYHA Class II or III), obstructive hypertrophic cardiomyopathy.

Hypertrophic Cardiomyopathy Epidemiology Forecast Markets 2018-2028 by Gender & 5 Year Age Cohort

Retrieved on: 
Friday, August 10, 2018
Cardiomyopathy, RTT, Sports medicine, Medicine, Anatomy, Clinical medicine, Hypertrophic cardiomyopathy, Exercise physiology, Hypertrophy, Genetic disorder, Hypertrophic cardiomyopathy screening, Arrhythmogenic right ventricular dysplasia

The "Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common transmitted genetic disease.
  • The disease, characterised by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension.
  • These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.